/
iJOURNAL  CLUB: Optimizing Therapy for Patients with Metastatic Squamous Cell Carcinoma iJOURNAL  CLUB: Optimizing Therapy for Patients with Metastatic Squamous Cell Carcinoma

iJOURNAL CLUB: Optimizing Therapy for Patients with Metastatic Squamous Cell Carcinoma - PowerPoint Presentation

berey
berey . @berey
Follow
345 views
Uploaded On 2022-06-11

iJOURNAL CLUB: Optimizing Therapy for Patients with Metastatic Squamous Cell Carcinoma - PPT Presentation

Interview with Shirish M Gadgeel MD January 14 2020 Case 1 72yearold woman enrolled on KEYNOTE021 2014 72yearold female patient with chest pain cough and dyspnea is diagnosed with Stage IV squamous cell carcinoma ID: 917382

patients lung afatinib cell lung patients cell afatinib squamous cancer oncol nsclc analysis 2019 mutations advanced carcinoma chemotherapy pfs

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "iJOURNAL CLUB: Optimizing Therapy for P..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

iJOURNAL CLUB: Optimizing Therapy for Patients with Metastatic Squamous Cell Carcinoma of the Lung

Interview with Shirish M

Gadgeel

, MD

January 14, 2020

Slide2

Case 1: 72-year-old woman enrolled on KEYNOTE-021

2014: 72-year-old female patient with chest pain, cough and dyspnea is diagnosed with Stage IV squamous cell carcinoma

Patient had lymph node and bone metastases

Enrolled on KEYNOTE-021 and received carboplatin, paclitaxel and pembrolizumab x 4 cycles followed by maintenance pembrolizumab

January 2016: Completed therapy; on surveillance

In 2014 it was not routine to assess tumor PD-L1

No recurrence of disease

Slide3

Case 1: 72-year-old woman enrolled on KEYNOTE-021

February 2014

October 2014

Slide4

The Evolving Use of Pembrolizumab in Combination Treatment Approaches for Non-Small Cell Lung Cancer

Alexander M

et al.

Expert Rev Respir Med

2020;14(2):137-47.

Slide5

The Evolving Use of Pembrolizumab in Combination Treatment Approaches for NSCLC

Alexander M et al.

Expert Rev Respir

Med 

2020;14(2):137-47.

Immune checkpoint inhibitors (ICI), particularly the anti-PD-1 inhibitor pembrolizumab (

pembro

), are now an established part of routine care for the majority of patients diagnosed with advanced NSCLC.

In the advanced setting, patients with PD-L1 TPS ≥50% benefit from

pembro

monotherapy, while a combination of

pembro

with chemotherapy is most beneficial for patients with PD-L1 TPS <50%.

Several studies have shown that consolidation ICI, including

pembro

, confers benefit for unresectable NSCLC after radiation therapy.

Validation of biomarkers other than PD-L1 TPS would be beneficial in identifying patients who would benefit from ICI to ensure a durable response, minimize immune-related adverse events and decrease treatment costs.

Slide6

Combination Pembrolizumab plus Chemotherapy: A New Standard of Care for Patients with Advanced Non-Small-Cell Lung Cancer

Weinberg F

et al.

Lung Cancer (

Auckl

)

2019;10:47-56.

Slide7

Front-Line Therapy for Advanced NSCLC

Weinberg F et al.

Lung Cancer (

Auckl

)

2019;10:47-56.

NSCLC

PD-L1 ≥50%

pembrolizumab

EGFR –

osimertinib

ALK –

alectinib

ROS1 –

crizotinib

BRAFV600E – dabrafenib + trametinib

PD-L1 ≥50%

pembrolizumab

(may consider chemo +

pembro

)

PD-L1 = 0%-49%

chemo +

pembro

PD-L1 = 0%-49%

chemo +

pembro

TMB may be assessed and if high

nivo

/

Ipi could be a consideration—CheckMate 227

Squamous

Marker-positive(EGFR, ALK, ROS1, BRAF)

Nonsquamous

Slide8

Results with Chemotherapy and Immunotherapy Trials for Advanced NSCLC

Weinberg F et al.

Lung Cancer (

Auckl

)

2019;10:47-56.

Trial

Treatment arm

PFS (months)

HR (95% CI)

OS

(months)

HR (95% CI)

KEYNOTE-21G

Pembrolizumab/platinum/pemetrexed

13

0.53 (0.31-0.91)

ND

0.90 (0.81-0.96)

KEYNOTE-189

Pembrolizumab/platinum/pemetrexed

8.8

0.52 (0.43-0.64)

NR

0.49 (0.38-0.64)

IMpower132

Atezolizumab

/platinum/pemetrexed

7.6

0.60 (0.49-0.72)

18.1

0.81 (0.64-1.03)

IMpower150

Atezo

/Carbo/Pac

Atezo

/Bev/Pac/Carbo

8.30.62 (0.52-0.74)19.20.78 (0.64-0.74)

Summary of results from chemotherapy + immunotherapy trials for patients with advanced nonsquamous NSCLC

PFS = progression-free survival; OS = overall survival; ND = not determined; NR = not reached; Atezo = atezolizumab; Carbo = carboplatin; Pac = paclitaxel; Bev = Bevacizumab

TrialTreatment armPFS (months)HR (95% CI)OS (months)HR (95% CI)KEYNOTE-407Pembrolizumab/Carbo/PacNab-Pac6.40.56 (0.45-0.70)15.90.64 (0.49-0.85)IMpower131Atezo/Platinum/PacNab-Pac6.30.72 (0.66-0.85)140.96 (0.78-1.18)

Summary of results from chemotherapy + immunotherapy trials for patients with advanced squamous NSCLC

Slide9

Hellmann MD

et al.

N

Engl

J Med

2019;381(21):2020-31.

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

Slide10

Hellmann MD et al.

N

Engl

J Med

2019;3

81(21):2020-31.

CheckMate

227: Overall Survival with Nivolumab/Ipilimumab versus Chemotherapy

First-line treatment with nivolumab and ipilimumab resulted in a longer duration of overall survival than did chemotherapy for patients with NSCLC, independent of PD-L1 expression level.

No new safety concerns emerged with longer follow-up.

Median OS (

mo

)

P-

value

Nivo

+

Ipi

Chemotherapy

PD-L1 ≥1% (n = 396, 397)

17.1

mo

14.9

mo

0.007

PD-L1 <1% (n = 187, 186)

17.2

mo

12.2

mo

Not reported

Slide11

Spigel

DR

et al.

Proc ESMO

2019;Abstract LBA78.

IMpower110: Interim Overall Survival (OS) Analysis of a Phase III Study of

Atezolizumab

(

Atezo

) vs Platinum-Based Chemotherapy (Chemo) as First-Line (1L) Treatment (

tx

) in PD-L1–Selected NSCLC

Slide12

IMpower110: Interim Overall Survival Analysis of Atezolizumab versus Platinum-Based Chemotherapy

At this interim analysis, IMpower110 met the primary OS endpoint with statistically significant and clinically meaningful improvement

with

atezolizumab

monotherapy 

in the TC3 or IC3 WT population.

Spigel

DR et al.

Proc ESMO

2019;

Abstract LBA78.

Atezolizumab

Chemotherapy

HR,

p-

value

n

Median OS (

mo

)

n

Median OS (

mo

)

TC3 or IC3 WT

107

20.2

98

13.1

0.59, 0.0106

TC2/3 or IC2/3 WT

166

18.2

162

14.9

0.72, 0.0416

TC1/2/3 or IC1/2/3 WT

277

17.527714.1

0.83, 0.1481

Slide13

Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-Life Experience at a Single Institution

Sukari

A

et al.

Anticancer Res

2019;39(2):781-90.

Slide14

Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors

Retrospective analysis of 168 patients who received ≥1 dose of single-agent PD-1 inhibitor.

Patients with renal cell carcinoma had higher odds of experiencing Grade 2 or higher kidney injury than patients with other primary tumor types (adjusted

p

= 0.025).

Patients with Hodgkin lymphoma or head and neck squamous cell carcinoma had higher odds of Grade 2 hypothyroidism (adjusted

p

= 0.005). Patients with NSCLC had higher risk of death with pneumonitis than those whose primary cancer was not NSCLC (adjusted

p = 0.005).When pneumonitis occurred in patients with primary NSCLC, the overall survival was significantly worse. The site of primary tumor or metastasis may help predict the most common AEs in patients who receive PD-1 inhibitors.

Sukari

A et al.

Anticancer Res

2019;39(2):781-90. 

Slide15

Afatinib versus Erlotinib as Second-Line Treatment of Patients with Advanced Squamous Cell Carcinoma of the Lung (LUX-Lung 8): An Open-Label Randomised Controlled Phase III Trial

Soria JC et al

.

Lancet Oncol

2015;16(8):897-907.

Slide16

Afatinib

(n = 398)

Erlotinib

(n = 397)

R

Phase III LUX-Lung 8 Trial Design

Primary endpoint:

Progression-free survival

Secondary endpoints included:

Overall survival, objective response rate

Eligibility (n = 795)

Stage IIIB or IV squamous cell carcinoma of the lung

Disease progression after at least four cycles of a first-line platinum-based regimen

Soria JC et al.

Lancet Oncol

2015;16(8):897-907.

1:1

Slide17

LUX-Lung 8: Primary Analysis of PFS and OS

Primary Endpoint: PFS

Primary analysis of OS demonstrated significantly greater OS in the

afatinib

group than in the erlotinib group (median 7.9

mo

vs 6.8

mo

; HR 0.81,

p

= 0.0077).

Soria JC et al.

Lancet Oncol

2015;16(8):897-907.

Slide18

LUX-Lung 8: Select Grade 3/4 Adverse Events

Adverse event profiles were similar in each group: 224 (57%) of 392 patients in the

afatinib

group versus 227 (57%) of 395 in the erlotinib group had grade 3 or higher adverse events.

Soria JC et al.

Lancet Oncol

2015;16(8):897-907.

AE

Afatinib

(n = 392)

Erlotinib (n = 395)

Grade 3

Grade 4

Grade 3

Grade 4

Diarrhea

10%

<1%

2%

<1%

Rash or acne

6%

0%

10%

0%

Stomatitis

4%

0%

0%

0%

Fatigue

2%

0%

2%

0%

Nausea

1%

0%

<1%

0%

Slide19

Second-Line Afatinib for Advanced Squamous Cell Carcinoma of the Lung: Analysis of Afatinib Long-Term Responders in the Phase III LUX-Lung 8 Trial

1

LUX-Lung 8 Phase III Trial: Analysis of Long-Term Response to Second-Line

Afatinib

in Patients with Advanced Squamous Cell Carcinoma (SCC) of the Lung

2

1

Goss G et al.

Proc IASLC 2016;Abstract OA23.03.2

Yang JC-H et al.Proc ELCC 2017;Abstract 102P.

Slide20

LUX-Lung 8: Post-hoc Analysis of Long-Term Responders (LTRs) with

Afatinib

Goss G et al.

Proc IASLC

2016;Abstract OA23.03; Yang JC-H et al.

Proc

ELCC

2017;Abstract 102P

.

N = 21 patients considered LTRs (

afatinib

treatment for ≥12 months).

Baseline characteristics of LTRs to

afatinib

were similar to that of the overall data set.

NGS data available for 10 LTRs and genomic aberrations in the ErbB gene family were identified in 50% of these pts (overall data set: 26.5%).

Other genomic aberrations more frequent in LTRs: EGFR, MLL, PIK3CA and KEAP1

Of 17 pts assessed by VeriStrat, 88% were VeriStrat-Good (overall data set: 62%).

Efficacy Endpoint

LTRs (N = 21)

Median PFS

16.6 months

Median OS

21.1 months

Slide21

Association of ERBB Mutations with Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients with Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial

Goss GD et al

.

JAMA Oncol

2018;4(9):1189-97.

Slide22

LUX-Lung 8: Secondary Analysis of ERBB Gene Family Mutations

Goss GD et al.

JAMA Oncol

2018;4(9):1189-97.

245 patients with PFS >2

mo

who were eligible for tumor genetic analysis (TGA)

Overall, the genetic characteristics of squamous cell carcinoma tumors in the TGA cohort were similar to those in the TCGA analysis

Frequency of ERBB Family Mutations in the Overall TGA Cohort and in

Patients Who Were LTRs to

Afatinib

Gene

TGA Subset (n = 245)

Afatinib

LTRs (n = 10)

ERBB wild type

78.4%

50.0%

ERBB mutation

EGFR

HER2

HER3

HER4

21.6%

6.5%

4.9%

6.1%

5.7%

50.0%

20.0%

20.0%

0%

10.0%

Slide23

LUX-Lung 8: Secondary Analysis of PFS and ERBB Gene Family Mutations and PFS

Goss GD et al.

JAMA Oncol

2018;4(9):1189-97.

For patients receiving

afatinib

, PFS was longer among patients with tumors with ERBB mutations than those without (median PFS: 4.9 vs 3.0 months; HR 0.62;

p

= 0.06).

Slide24

LUX-Lung 8: Secondary Analysis of PFS and ERBB Gene Family Mutations and OS

Goss GD et al.

JAMA Oncol

2018;4(9):1189-97.

For patients receiving

afatinib

, OS was longer among patients with tumors with ERBB mutations than those without (median OS: 10.6

mo

vs 8.1

mo

; HR, 0.75;

p

= 0.21).

Slide25

LUX-Lung 8: Secondary Analysis of PFS and OS Among Patients with and without EGFR, HER2, HER3 and HER4 Mutations

Goss GD et al.

JAMA Oncol

2018;4(9):1189-97.

Slide26

EDITORIAL: Association of ERBB Mutations with Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients with Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial

Gandara DR et al

.

JAMA Oncol

2018;4(9):1197-8.

Slide27

Gandara DR et al.

JAMA Oncol

2018;4(9):1197-8.

“… no substantial progress has been made in the clinical application of targeted therapy for patients with squamous cancers … despite the discovery of a number of potential molecular targets and the initiation of associated clinical trials.”

“Thus, the study by Goss et al in this issue of JAMA Oncology identifying ERBB family mutations as potential oncogenic drivers in squamous lung cancer is timely.”

“For those squamous lung cancers found to harbor an oncogenic ERBB mutation, treatment with

afatinib

appears to be a reasonable option as second- or third-line therapy dependent on the initial treatment regimen.”

Slide28

Activity of Afatinib in Heavily Pretreated Patients with ERBB2 Mutation-Positive Advanced NSCLC: Findings from a Global Named Patient Use Program

Peters S et al

.

J Thoracic Oncol

2018;13(12):1897-905.

Slide29

Patients with any ERBB2 mutation

(n = 28)

Patients with

p.A775_G776insYVMA

in Exon 20 (n =10)

Patients with

M774dup in

Exon 20 (n = 2)

Median TTF

2.9

mo

9.6

mo

1.9

mo

ORR/PR

19.0%/19.0%

33.0%/33.0%

ND/ND

Efficacy of

Afatinib

and Types of ERBB2 Mutations Detected in Patients Enrolled in Global Named Patient Use Program*

Peters S et al.

J Thoracic Oncol

2018;13(12):1897-905.

*

Patients with Stage IV lung adenocarcinoma that progressed after clinical benefit on erlotinib/gefitinib and/or had activating EGFR or ERBB2 mutations, had exhausted other treatments and were ineligible for

afatinib

trials

10

162

Slide30

Updated Results of Phase I Study of DS-8201a in HER2-Expressing or -Mutated Advanced Non-Small-Cell Lung Cancer

Tsurutani

J

et al.

Proc IASLC

2018;Abstract OA02.07.

Slide31

Phase I Study of DS-8201a for Patients with NSCLC with HER2 Expression or Mutation

Patients (n = 12) with NSCLC with HER2 expression or mutations who had received a median of 3 prior regimens received ≥1 dose of DS-8201a.

Eight of 10 (80.0%) patients with ≥1 postbaseline scan experienced tumor shrinkage (100% of them at first postbaseline scan at 6 weeks).

Overall, confirmed ORR and DCR for the evaluable patients were 5 of 8 (62.5%) and 6 of 8 (75.0%), respectively.

Among patients with HER2 IHC 2+ or IHC 3+ expression, 2 of 5 (40.0%) had a PR.

Common AEs included decreased appetite 66.7% (0.0% Grade ≥3), nausea

58.3% (0.0% Grade ≥3), alopecia 41.7% (0.0% Grade ≥3) and fatigue 41.7%

(0.0% Grade ≥3).

One fatal case of interstitial lung disease was reported in this subgroup.

Tsurutani

J

et al.

Proc IASLC

2018;Abstract OA02.07

Slide32

Ado-Trastuzumab Emtansine for Patients with HER2-Mutant Lung Cancers: Results from a Phase II Basket Trial

Li BT

et al.

J Clin Oncol

2018;36(24):2532-7.

Slide33

Phase II Trial of T-DM1 for Lung Cancers with HER2 Mutation

Patients (n = 18) with advanced lung adenocarcinomas with HER2 mutations (median no. of prior therapies was 2) received T-DM1 until disease progression

Partial response rate: 44% (primary endpoint was met)

Responses were observed in patients with HER2 exon 20 insertions and point mutations in the kinase, transmembrane and extracellular domains

Median PFS: 5 months

Toxicities included Grade 1 and 2 infusion reactions, thrombocytopenia and elevated hepatic transaminases

Li BT et al.

J Clin Oncol

2018;36(24):2532-7

Slide34

Afatinib in Patients with Metastatic or Recurrent HER2-Mutant Lung Cancers: A Retrospective International Multicentre Study

Lai WV et al

.

Eur J Cancer

2019;109:28-35.

Slide35

Efficacy of

Afatinib

and Types of HER2 Mutations Detected in Patients Enrolled in Retrospective International Multicenter Study*

Lai WV et al.

Eur J Cancer

2019;109:28-35.

*

Eligible patients from 7 institutions who had a pathologic diagnosis of advanced (Stage IV or recurrent) lung adenocarcinoma and a HER2 mutation by a validated molecular diagnostic test that was performed in an accredited local laboratory

HER2 mutation

Mutation amino acid change

(nucleotide change)

Frequency

(%)

Partial

response

Progressive

disease

Exon 20 insertion (12bp)

p.A775_G776insYVMA (c.2324_2325ins12)

15 (54)

n = 2

n = 2

Exon 20 insertion (12bp)

p.A775_G776insAVMA

1 (4)

Exon 20 insertion (9bp)

p.A775_G776lnsVAG (c.2325_2326lns 9)

2 (7)

n = 1

Exon 20 insertion (9bp)

p.P780_Y781

insGSP

(c.2339_2340ins 9)

1 (4)

n = 1

Exon 20 insertion (3bp)

p.G776>VC (c.2326_2327insTGT)

1 (4)

Exon 20 insertion (3bp)

Not specified

1 (4)n = 1Exon 20 single bp substitutionP.D769H (C.2305 G>C)1 (4)n = 1Exon 20 single bp substitutionp.L755F1 (4)n = 1Exon 17 single bp substitutionP.V659E (c.1976_1977delinsAA)1 (4)n = 1Exon 8 single bp substitutionP.S310F (c.929C>T)2 (7)

Single-nucleotide polymorphism

lle655Val

1 (4)

Slide36

Case 2: 82-year-old man diagnosed with Stage III squamous cell carcinoma of the lung develops liver metastases

An 82-year-old man diagnosed with Stage III squamous cell carcinoma of the lung

Receives chemoradiation therapy followed by

durvalumab

Develops liver metastases

NGS shows FGFR1 amplification (approximately 9 copies)

Receives carboplatin/paclitaxel, 4 cycles, with stable disease

Disease progression a few months laterPatient is considered for gemcitabine and afatinib. Decides to start gemcitabine but is very fatigued and opts to enroll in hospice

Slide37

Comprehensive Genomic Characterization of Squamous Cell Lung Cancers

Cancer Genome Atlas Research Network.

Nature

2012;489(7417):519-25.

Slide38

Significantly Mutated Genes in Squamous Cell Carcinoma (

SqCC

) of the Lung Identified by Whole Exome Sequencing

Cancer Genome Atlas Research Network.

Nature

2012;489(7417):519-25.

As part of The Cancer Genome Atlas, 178 samples of

SqCC

of the lung samples were profiled

Syn.

Non syn.

# mutations/Mb

70

50

30

10

# individuals with mutations

100

80

60

40

20

0

81%

15%

8%

16%

12%

20%3%15%8%7%Syn.MissenseSplice siteNonsenseFrame shiftIn frame indelOther non syn.TP53CDKN2APTENPIK3CAKEAP1MLL2HLA-ANFE2L2NOTCH1RB10.5

2.03.5-log (q-value)

Slide39

Lung Master Protocol (Lung-MAP) — A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400

Herbst RS et al.

Clin Cancer Res

2015;21(7):1514-24.

Slide40

S1400: Lung-MAP Trial Design

Herbst RS et al.

Clin Cancer Res

2015;21(7):1514-24.

CT

CT = chemotherapy (

docetaxel

or gemcitabine)

;

E =

erlotinib

FGFRi

+ CT

CT

Primary Endpoint

OS

FGFR

ampl

,

Mut

, Fusion

CDK4/6i

CT

Primary Endpoint

OS

CCND1

ampl

or CDK4/6

ampl

or

CDKN2 loss + RB WT

PI3Ki

CT

Primary Endpoint

OS

PiK3CA

Mut

Biomarker

Profiling (NGS/CLIA)

HGFi

+ EEPrimary EndpointOSMET Expr(IHC score)PD-L1i BiomarkerNon-Match

Multiple Phase II-

III arms

with

rolling opening & closure”

Slide41

SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

Langer CJ et al.

J

Thorac

Oncol

2019;14(10):1839-46.

Slide42

SWOG S1400C (NCT02154490) — A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)

Edelman MJ et al.

J

Thorac

Oncol

2019;14(10):1853-9.

Slide43

SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients with Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)

Aggarwal C et al.

J

Thorac

Oncol

2019;14(10):1847-52.

Slide44

Updated Results of Completed Phase II Lung-MAP

Substudies

1

Langer CJ et al.

J

Thorac

Oncol

2019;14(10):1839-46;

2

Edelman MJ et al.

J

Thorac

Oncol

2019;14(10):1853-9;

3

Aggarwal C et al.

J

Thorac

Oncol

2019;14(10):1847-52.

Substudy

Evaluable Patients

Response:

Patients (%)

Median PFS

Median OS

SWOG S1400B

1

(NCT02785913)Taselisib: 21

1 (5%)2.9 mo

5.9 moSWOG S1400C2(NCT02154490)

Palbociclib: 322 (6%)

1.7 mo7.1 mo

SWOG S1400D3(NCT02965378)

AZD4547: 272 (7%)

2.7

mo

7.5

mo

Slide45

Case 3: 52-year-old woman with metastatic NSCLC with an ALK rearrangement experiences a dramatic response to crizotinib

A 52-year-old woman diagnosed in 2010 with metastatic lung adenocarcinoma and spinal cord compression was admitted to hospice care at home in December 2010

She checked out of hospice to enroll in the PROFILE 1014 study randomly assigning patients with NSCLC with ALK rearrangements to

crizotinib

versus chemotherapy

She was randomly assigned to chemotherapy and attained stable disease 

She crossed over to the

crizotinib

arm in February 2012 and experienced a dramatic response The patient developed disease progression in the brain in June 2014 and was switched to

ceritinib but did not tolerate itShe was switched to alectinib with a CR in the brain and is currently on therapy with this drug